3,149,907 Shares in Shattuck Labs, Inc. $STTK Acquired by NEXTBio Capital Management LP

NEXTBio Capital Management LP bought a new position in shares of Shattuck Labs, Inc. (NASDAQ:STTK) in the 4th quarter, HoldingsChannel.com reports. The firm bought 3,149,907 shares of the company’s stock, valued at approximately $11,497,000. Shattuck Labs accounts for about 6.7% of NEXTBio Capital Management LP’s portfolio, making the stock its 5th biggest position.

Several other institutional investors have also recently added to or reduced their stakes in the business. Orbimed Advisors LLC purchased a new stake in Shattuck Labs in the third quarter valued at approximately $15,072,000. Pinnacle Associates Ltd. lifted its stake in Shattuck Labs by 1.8% in the third quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock valued at $3,319,000 after buying an additional 25,000 shares during the last quarter. Bank of America Corp DE lifted its stake in Shattuck Labs by 2,968.2% in the third quarter. Bank of America Corp DE now owns 1,131,888 shares of the company’s stock valued at $2,705,000 after buying an additional 1,094,997 shares during the last quarter. Geode Capital Management LLC lifted its stake in Shattuck Labs by 32.1% in the fourth quarter. Geode Capital Management LLC now owns 618,277 shares of the company’s stock valued at $2,258,000 after buying an additional 150,318 shares during the last quarter. Finally, Aberdeen Group plc lifted its stake in Shattuck Labs by 462.1% in the fourth quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock valued at $1,939,000 after buying an additional 436,673 shares during the last quarter. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Price Performance

Shares of STTK stock opened at $4.94 on Friday. The business’s fifty day moving average price is $6.35 and its 200 day moving average price is $4.94. Shattuck Labs, Inc. has a 1-year low of $0.71 and a 1-year high of $8.33. The firm has a market capitalization of $378.80 million, a PE ratio of -7.84 and a beta of 1.08.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. During the same period last year, the business posted ($0.27) EPS. Equities research analysts expect that Shattuck Labs, Inc. will post -0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on STTK. Needham & Company LLC boosted their price objective on Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Wedbush boosted their price objective on Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Citigroup upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, June 5th. Weiss Ratings cut Shattuck Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. Finally, Jefferies Financial Group upgraded Shattuck Labs to an “outperform” rating and set a $7.00 price objective for the company in a research note on Friday, June 5th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Insider Buying and Selling at Shattuck Labs

In other news, Director Clay B. Siegall bought 62,500 shares of the stock in a transaction on Tuesday, June 9th. The shares were bought at an average price of $4.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the director owned 318,608 shares of the company’s stock, valued at approximately $1,274,432. This trade represents a 24.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Arundathy N. Pandite sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total value of $198,300.00. Following the completion of the sale, the insider directly owned 166,219 shares in the company, valued at $1,098,707.59. This trade represents a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.79% of the stock is currently owned by corporate insiders.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.